Vasopressin vs Terlipressin

Vasopressin and Terlipressin are structurally related peptides with overlapping yet distinct research applications. Vasopressin, an endogenous hormone, primarily regulates water balance and vascular tone through V2 and V1a receptors, respectively. Terlipressin, a synthetic prodrug, is slowly converted to lysine-vasopressin, offering prolonged V1a receptor activation. This comparison examines their mechanisms, evidence bases, dosing protocols, and safety profiles, emphasizing how their differences inform research design in reproductive and critical care studies.

Vasopressin (arginine vasopressin, AVP) is an endogenous cyclic nonapeptide (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2, MW ~1084.2 g/mol) synthesized in the hypothalamus and released from the posterior pituitary. It exerts its effects via two primary receptor subtypes: V2 receptors in the renal collecting ducts, which promote water reabsorption, and V1a receptors on vascular smooth muscle, which mediate vasoconstriction. Synthetic vasopressin (Vasostrict) is FDA-approved for vasodilatory shock and has been studied in diabetes insipidus, esophageal variceal bleeding, and cardiac arrest. Research indicates its efficacy in improving mean arterial pressure in shock states, though its use in cardiac arrest algorithms remains debated. The evidence for vasopressin in reproductive health is emerging, focusing on uterine contractility and placental perfusion.

Terlipressin is a synthetic vasopressin analog (MW ~1227.4 g/mol) designed as a prodrug, with slow enzymatic conversion to lysine-vasopressin via tissue peptidases. This conversion provides sustained activation of V1a receptors, leading to pronounced splanchnic vasoconstriction. In September 2022, terlipressin (Terlivaz) received FDA approval for hepatorenal syndrome type 1 (HRS-1), marking the first pharmacotherapy specifically indicated for this condition in the United States. Prior to this, it had been used in Europe for decades to manage acute variceal bleeding and HRS. Preclinical models suggest terlipressin improves renal perfusion by reducing portal pressure, though its efficacy in reproductive health applications remains underexplored compared to vasopressin.

Both vasopressin and terlipressin are investigated in reproductive health and critical care contexts. In reproductive health, vasopressin is studied for its role in uterine contractility and placental blood flow regulation, while terlipressin's applications are less defined. In critical care, both peptides are evaluated for hemodynamic support in shock states; vasopressin is used in vasodilatory shock, whereas terlipressin is primarily studied for hepatorenal syndrome and variceal bleeding. Notably, vasopressin has no unique applications beyond these shared areas, and terlipressin similarly lacks additional distinct research domains. This overlap underscores the need for careful mechanistic selection in experimental designs.

Vasopressin use is associated with peripheral and splanchnic ischemia, including digital ischemia, mesenteric ischemia, and skin necrosis, particularly at higher doses. Cardiac ischemia due to coronary vasoconstriction may precipitate angina or myocardial infarction. Hyponatremia can occur from excessive water retention via V2 receptor stimulation. Terlipressin carries a notable risk of respiratory failure, observed in 11% of treated patients versus 2% in the placebo arm of the CONFIRM trial, leading to an FDA boxed warning. Common adverse effects include abdominal pain and diarrhea. Peripheral ischemia, such as digital necrosis and intestinal ischemia, has also been reported. These safety profiles highlight the importance of dose optimization and monitoring in research protocols.